Compare Gitlab Inc (GTLB) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Gitlab Inc trades at $55.09 (market cap $8.92B), while Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B). The key difference: Halozyme Therapeutics Inc. Common Stock is the larger of the two by market cap, and Gitlab Inc is more actively traded (4,716,893 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| GTLB | HALO | |
|---|---|---|
Market Cap | $8.92B | $12.58B |
Volume | 4,716,893 | 2,179,278 |
Sector | Technology | Health |
52-Week High | $55.09 | $115.22 |
52-Week Low | $19.42 | $61.63 |
Typical Hold Time | 62 Days | 1 Days |
Enterprise Value | $7.66B | $14.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $53.56, up 3.02% today and near its 52-week high, with strong technical momentum indicated by moving averages. The company shows impressive revenue growth, reaching $759 million in 2025, but remains unprofitable with a negative net income margin of -4.99%. Recent Q2 2026 earnings beat expectations, and the stock surged on raised guidance and AI-driven demand optimism.
Outlook: GitLab benefits from AI integration in software development and strong sales momentum, but high valuation multiples (P/E 521) and persistent losses pose risks. Analyst consensus is mixed with a $49.71 price target below current levels, suggesting cautious optimism amid execution challenges and competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
